Pediatrix Medical Group (NYSE:MD) Downgraded to Hold Rating by StockNews.com

Pediatrix Medical Group (NYSE:MD) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other brokerages have also commented on MD. Jefferies Financial Group boosted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Truist Financial raised their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Mizuho upped their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday. Finally, UBS Group increased their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $14.49 on Thursday. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -4.74, a price-to-earnings-growth ratio of 2.03 and a beta of 1.55. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The firm has a 50 day moving average of $12.77 and a 200-day moving average of $9.96. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. During the same period last year, the business posted $0.29 EPS. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. On average, equities analysts forecast that Pediatrix Medical Group will post 1.25 earnings per share for the current year.

Insider Activity

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,808 shares of company stock valued at $751,277 in the last three months. Company insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MD. Aristeia Capital L.L.C. purchased a new position in Pediatrix Medical Group during the 2nd quarter valued at about $687,000. Vanguard Group Inc. increased its holdings in Pediatrix Medical Group by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after acquiring an additional 164,333 shares during the period. Boston Partners lifted its stake in Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares in the last quarter. Rubric Capital Management LP boosted its holdings in Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares during the period. Finally, ClariVest Asset Management LLC purchased a new position in shares of Pediatrix Medical Group during the 2nd quarter valued at $1,721,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.